Four patient procedures per second supported by our products¹
employees worldwide
revenue in 2023²
We have seven GE HealthCare-owned, vertically integrated plants, all current good manufacturing process (cGMP)- accredited, producing active ingredient through to finished product. Over the past decade we have invested almost $400 million to increase manufacturing capacity to address growing global demand.
We have multiple programmes in pre-clinical and clinical phases across contrast media and molecular imaging with research and development hubs located in:
• Amersham, UK
• Marlborough, US
• Oslo, Norway
• Shanghai, China
• Toulouse, France
We also partner with top academic centres in the US, Europe, and Asia.
We are committed to the efficient use of resources required for producing and delivering our imaging agents whilst minimizing our impact on the environment. We also support customers to optimize contrast media use where possible.
